Related Experiment Videos
Minimising the risks of allergen-specific injection immunotherapy
1Allergy Unit, National University Hospital, Copenhagen, Denmark. all-unit@rh.dk
Drug Safety
|October 29, 2000
Summary
Allergen immunotherapy offers clinical benefits but carries risks of systemic reactions, including anaphylaxis. Careful patient selection, dose management, and staff training are crucial for minimizing adverse effects and ensuring patient safety.
Area of Science:
- Immunology
- Clinical Allergy
- Pharmacovigilance
Background:
- Allergen-specific immunotherapy (AIT) provides clinical advantages for allergic diseases.
- However, AIT is associated with the risk of systemic adverse effects, including potentially life-threatening anaphylactic reactions.
- Effective risk management is essential for safe AIT administration.
Purpose of the Study:
- To review and outline strategies for minimizing systemic adverse effects during allergen immunotherapy.
- To emphasize the importance of risk assessment, patient monitoring, and standardized procedures.
- To discuss factors influencing the risk of adverse reactions and methods for their mitigation.
Main Methods:
- Review of current literature and clinical guidelines on allergen immunotherapy safety.
- Analysis of risk factors, adverse event grading systems, and preventive measures.
- Discussion of different immunotherapy induction regimens and their safety profiles.
- Emphasis on the role of healthcare professionals, patient education, and quality assurance.
Main Results:
- Uncontrolled asthma is a significant risk factor for systemic reactions.
- Dose escalation, especially during pollen seasons, increases adverse event risk.
- Standardized allergen extracts and careful dose adjustments are vital to prevent overdose.
- Clustered induction regimens offer a balance between speed and safety compared to rush immunotherapy.
- Minimizing human error through meticulous monitoring, staff training, and patient involvement is key.
- Prompt recognition and treatment of anaphylaxis are critical for successful outcomes.
Conclusions:
- Implementing standardized protocols, identifying at-risk patients, and rigorous monitoring are fundamental to AIT safety.
- Optimizing immunotherapy regimens and minimizing human error can significantly reduce adverse events.
- A comprehensive quality assurance program is the most effective approach to minimize immunotherapy-associated systemic reactions.